Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hodgkin Disease 2Sezary Syndrome 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Cytomegalovirus Infections 1

Interventions

Valganciclovir 3Valacyclovir 2Polymerase Chain Reaction 2Flow Cytometry 2Cell Count 2Blood Specimen Collection 2letermovir 1dolutegravir 1Zidovudine 1VCL-CB01 vaccine 1Stem Cell Transplantation 1Specimen Handling 1Ritonavir 1Peripheral Blood Stem Cell Transplantation 1Nucleosides 1Immunologic Techniques 1Ganciclovir 1Darunavir 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cytomegalovirus Infections × letermovir × Clear all
NCT04017962 2025-08-11

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 13 charts

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡